Scar - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Scar - Pipeline Review, H2 2018’, provides an overview of the Scar pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Scar, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Scar and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Scar

- The report reviews pipeline therapeutics for Scar by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Scar therapeutics and enlists all their major and minor projects

- The report assesses Scar therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Scar

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Scar

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abzena Plc

Altacor Ltd

BirchBioMed Inc

Cotinga Pharmaceuticals Inc

Kringle Pharma Inc

Moerae Matrix Inc

Pharmaxis Ltd

Promore Pharma AB

Resolys Bio Inc

RXi Pharmaceuticals ...

Abzena Plc

Altacor Ltd

BirchBioMed Inc

Cotinga Pharmaceuticals Inc

Kringle Pharma Inc

Moerae Matrix Inc

Pharmaxis Ltd

Promore Pharma AB

Resolys Bio Inc

RXi Pharmaceuticals Corp

Synedgen Inc

Vascular BioSciences

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Scar – Overview

Scar – Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Scar – Overview

Scar – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Scar – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Scar – Companies Involved in Therapeutics Development

Abzena Plc

Altacor Ltd

BirchBioMed Inc

Cotinga Pharmaceuticals Inc

Kringle Pharma Inc

Moerae Matrix Inc

Pharmaxis Ltd

Promore Pharma AB

Resolys Bio Inc

RXi Pharmaceuticals Corp

Synedgen Inc

Vascular BioSciences

Scar – Drug Profiles

albuterol – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTL-slo – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

decorin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Evitar – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FS-2 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein for Scar – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICX-RHY – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-100IT – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

magacizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MG-53 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MMI-0100 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Fibrotic Scar – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nefopam hydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polysaccharide for Wounds and Scars – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXL-01 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXI-109 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Lysyl Oxidase for Scar and Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit SOX-9 for Scar – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tranilast – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Scar – Dormant Projects

Scar – Discontinued Products

Scar – Product Development Milestones

Featured News & Press Releases

May 08, 2018: RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO

Feb 16, 2018: BirchBioMed is cleared to begin first-of-its-kind phase II clinical trial for ground-breaking anti-scarring drug

Feb 15, 2018: Promore Pharma Regains Rights for PXL01 Manufacturing

Feb 01, 2018: Promore Pharma is granted a patent for PXL01 in the US

Jan 02, 2018: Promore Pharma Adjusts Plans for PXL01 in North America

Dec 18, 2017: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring

Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017

May 17, 2017: Promore Pharma files phase III clinical trial application in India

Mar 28, 2017: RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109

Aug 25, 2016: BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug

Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream

Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model

Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference

Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109

Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Scar, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Scar, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Scar – Pipeline by Abzena Plc, H2 2018

Scar – Pipeline by Altacor Ltd, H2 2018

Scar – Pipeline by BirchBioMed Inc, H2 2018

Scar – Pipeline by Cotinga Pharmaceuticals Inc, H2 2018

Scar – Pipeline by Kringle Pharma Inc, H2 2018

Scar – Pipeline by Moerae Matrix Inc, H2 2018

Scar – Pipeline by Pharmaxis Ltd, H2 2018

Scar – Pipeline by Promore Pharma AB, H2 2018

Scar – Pipeline by Resolys Bio Inc, H2 2018

Scar – Pipeline by RXi Pharmaceuticals Corp, H2 2018

Scar – Pipeline by Synedgen Inc, H2 2018

Scar – Pipeline by Vascular BioSciences, H2 2018

Scar – Dormant Projects, H2 2018

Scar – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Scar, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Scar, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports